Your browser doesn't support javascript.
loading
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson, Andrew Dj; Stegmaier, Kimberly; Bourdeaut, Franck; Reaman, Gregory; Heenen, Delphine; Meyers, Michael L; Armstrong, Scott A; Brown, Patrick; De Carvalho, Daniel; Jabado, Nada; Marshall, Lynley; Rivera, Miguel; Smith, Malcolm; Adamson, Peter C; Barone, Amy; Baumann, Christian; Blackman, Samuel; Buenger, Vickie; Donoghue, Martha; Duncan, Aundrietta D; Fox, Elizabeth; Gadbaw, Brian; Hattersley, Maureen; Ho, Peter; Jacobs, Ira; Kelly, Michael J; Kieran, Mark; Lesa, Giovanni; Ligas, Franca; Ludwinski, Donna; McDonough, Joe; Nikolova, Zariana; Norga, Koen; Senderowicz, Adrian; Taube, Tilmann; Weiner, Susan; Karres, Dominik; Vassal, Gilles.
Afiliação
  • Pearson AD; Accelerate, UK. Electronic address: andy1pearson@btinternet.com.
  • Stegmaier K; Dana-Faber Cancer Institute/Harvard Medical School, USA.
  • Bourdeaut F; Institute Curie, France.
  • Reaman G; US Food and Drug Administration, USA.
  • Heenen D; KickCancer Foundation, Belgium.
  • Meyers ML; Syndax Pharmaceuticals Inc, USA.
  • Armstrong SA; Dana-Faber Cancer Institute/Harvard Medical School, USA.
  • Brown P; Johns Hopkins Hospital, USA.
  • De Carvalho D; University Health Network, Canada.
  • Jabado N; McGill University Health Centre, Canada.
  • Marshall L; Royal Marsden NHS Foundation Trust/Institute of Cancer Research, UK.
  • Rivera M; Massachusetts General Hospital, USA.
  • Smith M; National Cancer Institute, USA.
  • Adamson PC; Sanofi US, Emeritus Professor of Paediatrics and Pharmacology, Perelman School of Medicine, University of Pennsylvania, USA.
  • Barone A; US Food and Drug Administration, USA.
  • Baumann C; GlaxoSmithKline, USA.
  • Blackman S; Day on Therapeutics Inc, USA.
  • Buenger V; Coalition Against Childhood Cancer, USA.
  • Donoghue M; US Food and Drug Administration, USA.
  • Duncan AD; Salarius Pharma, USA.
  • Fox E; St Jude Children's Research Hospital, USA.
  • Gadbaw B; Novartis Pharmaceuticals Corp, USA.
  • Hattersley M; AstraZeneca, USA.
  • Ho P; Boston Pharmaceuticals, USA.
  • Jacobs I; Pfizer, USA.
  • Kelly MJ; Syros Pharmaceuticals, USA.
  • Kieran M; Bristol Myers Squibb, USA.
  • Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Ludwinski D; Solving Kids' Cancer, USA.
  • McDonough J; The Andrew McDonough B+ Foundation, USA.
  • Nikolova Z; Celgene, Switzerland.
  • Norga K; Antwerp University Hospital, Paediatric Committee of the European Medicines Agency, Federal Agency for Medicines and Health Products, Belgium.
  • Senderowicz A; Constellation Pharma, USA.
  • Taube T; Boehringer Ingelheim, Germany.
  • Weiner S; Children's Cancer Cause, USA.
  • Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands.
  • Vassal G; Gustave Roussy Cancer Centre, France.
Eur J Cancer ; 139: 135-148, 2020 11.
Article em En | MEDLINE | ID: mdl-32992153
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epigênese Genética / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epigênese Genética / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article